Lactobacillus crispatus 30 capsules (3 billion CFU/capsule)


The use of Lactobacillus crispatus probiotics are effective against bacterial vaginosis and vulvovaginal candidiasis being suitable for both vaginal and oral administration1. L. crispatus supplementation contributes to lowering the recurrence of bacterial vaginosis2 and significantly reducing H. pylori load3. Daily intake of L. crispatus KT-11 can prevent periodontal disease through the improvement of oral conditions4. L. crispatus dominated cervicovaginal microbiota are associated with a lower prevalence of HIV and STIs5.


Dosage: 3 billion CFU per capsule

Capsules per order: 30 capsules

Instructions: 1 capsule daily (morning)


  1. Mändar R, Sõerunurk G, Štšepetova J, Smidt I, Rööp T, Kõljalg S, Saare M, Ausmees K, Le DD, Jaagura M, Piiskop S, Tamm H, Salumets A. Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial. Benef Microbes. 2023 Apr 18;14(2):143-152.
  2. Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020 May 14;382(20):1906-1915.
  3. Hong Q, Wang J, Zhang H, Liu X, Liu Z. Study of the effect of Lactobacillus crispatus FSCDJY67L3 on Helicobacter Pylori eradication: a double-blind randomized controlled clinical trial. Front Immunol. 2023 Oct 26;14:1265995.
  4. Tobita K, Watanabe I, Tomokiyo M, Saito M. Effects of heat-treated Lactobacillus crispatus KT-11 strain consumption on improvement of oral cavity environment: a randomised double-blind clinical trial. Benef Microbes. 2018 Jun 15;9(4):585-592.
  5. Borgdorff H, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Schuren FH, van de Wijgert JH. Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. ISME J. 2014 Sep;8(9):1781-93.